Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

carefusion switzerland 317 sárl also trading as cardinal health, a-one business centre, zone d´activités vers-la-piéce no 10 rolle Švajčiarsko -

Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

carefusion switzerland 317 sárl also trading as cardinal health, a-one business centre, zone d´activités vers-la-piéce no 10 rolle Švajčiarsko -

Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

carefusion switzerland 317 sárl also trading as cardinal health, a-one business centre, zone d´activités vers-la-piéce no 10 rolle Švajčiarsko -

Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

carefusion switzerland 317 sárl also trading as cardinal health, a-one business centre, zone d´activités vers-la-piéce no 10 rolle Švajčiarsko -

Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

carefusion switzerland 317 sárl also trading as cardinal health, a-one business centre, zone d´activités vers-la-piéce no 10 rolle Švajčiarsko -

Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

carefusion switzerland 317 sárl also trading as cardinal health, a-one business centre, zone d´activités vers-la-piéce no 10 rolle Švajčiarsko -

Evropská unie - slovenština - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin - diabetes mellitus, typ 2 - lieky používané pri cukrovke - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5.

Evropská unie - slovenština - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artritída, reumatoidná artritída - imunosupresíva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 a 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Evropská unie - slovenština - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic kyseliny, sitagliptin fosfát monohydrát - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - steglujan je indikovaný u dospelých vo veku 18 rokov a starších s diabetes mellitus 2. typu ako doplnok stravy a cvičenia na zlepšenie glykemický ovládanie:keď metformínom a/alebo sulfonylmocoviny (su) a jeden z monocomponents z steglujan neposkytujú dostatočnú glykemický ovládanie. u pacientov už liečená kombinácia ertugliflozin a sitagliptin ako samostatné tablety.

Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

terumo cardiovascular systems corporation 6200 jackson road 48103 annarbor, michigan spojené štáty americké -